Labiotech.eu

News and Trends 24 Oct 2022

Beckley Psytech acquires Eleusis Therapeutics

Beckley Psytech Limited has entered into a definitive agreement to acquire clinical-stage life science company Eleusis Therapeutics Limited in an all equity transaction. Under the terms of the agreement, which has been approved by shareholders, Beckley Psytech has acquired 100% of Eleusis, receiving full developmental and commercial rights for the company’s assets, which will further […]

October 24, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 24 Oct 2022

Syncona to acquire Applied Genetic Technologies Corporation

Healthcare company Syncona Limited says its newly established portfolio company has agreed to acquire, by a tender offer, all outstanding shares of Applied Genetic Technologies Corporation (AGTC). AGTC is a clinical-stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an […]

October 24, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 24 Oct 2022

New method of observing cell transport could inspire drug development

Membrane proteins are key targets for many drugs. Some of them, called transporters, move certain substances in and out of the cellular environment. Yet, extracting and storing them for observation is particularly complex. A team from the University of Geneva (UNIGE) in Switzerland, in collaboration with the University of Zurich (UZH), has developed an innovative […]

October 24, 2022 - 4 minutesmins - By Jim Cornall

More News! 24 Oct 2022

Sensorion gets go-ahead from France for trial of drug to prevent hearing loss

Biotech company, Sensorion, today (October 24) announced that the initiation of a proof of concept (PoC) clinical trial of SENS-401 (Arazasetron) in patients with Cisplatin-Induced Ototoxicity (CIO) has been approved by the regulatory authorities in France. Cisplatin and other platinum-based compounds are essential chemotherapeutic agents for many cancers. A serious side effect of these therapies […]

October 24, 2022 - 3 minutesmins - By Liza Laws

More News! 24 Oct 2022

Mass production of lutetium for targeted cancer therapeutics following collaboration

An international collaboration marking the start of commercial production of lutetium-177 was celebrated in Munich between Canada-based Bruce Power, Isogen and Isotope Technologies Munich (ITM). The announcement was celebrated along with representatives of the partnership organizations during a trade mission with Vic Fedeli, Ontario’s Minister of Economic Development, Job Creation and Trade. This milestone was […]

October 24, 2022 - 4 minutesmins - By Liza Laws

Opinion 24 Oct 2022

Hiding in plain sight: how to solve bioscience’s software problem

Guy Levy-Yurista, CEO of the experiment platform developer Synthace, gives his take on what’s missing in increasingly software-dependent life sciences labs: a holistic mindset for improving experimental methods. There’s a major problem holding back progress in biotech, and more widely in the life sciences. It’s not an obvious one, but based on the conversations I […]

October 24, 2022 - 5 minutesmins - By External Contributor

News and Trends 21 Oct 2022

Watch: NLS Days NLSInvest award winners – MyoPax

The two biotech start-up companies MyoPax and Asgards Therapeutics won first and second prize at NLSINvest Awards, out of 40 companies that participated in Nordic Life Science Days’ start-up pitching challenge. 40 selected Nordic start-up companies attended Nordic Life Science Days, the largest partnering conference for life sciences in the Nordics, in Malmö. As part […]

October 21, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 21 Oct 2022

Beyond Biotech podcast 19: Bone Health Technologies, Immutep, TAU Systems

This week, we have three guests. We have conversations with Marc Voigt, CEO of Immutep; Manuel Hegelich, CEO of TAU Systems; and Laura Yecies, CEO of Bone Health Technologies. We also have our weekly chat with global commercial real estate services company JLL, with Travis McCready. FDA fast tracks Immutep non-small cell lung cancer candidate […]

October 21, 2022

Inside Labiotech 21 Oct 2022

Meet Bárbara, our new sales representative

We’re very excited to welcome Bárbara to our team! She will be working with us to help the biopharma and biotech industries connect and grow. Let’s take a look at why she decided to join us and her ambitions with Labiotech. Bárbara Leite, Sales Representative From Porto, Portugal Bárbara, to start with, how would you […]

October 21, 2022 - 3 minutesmins - By Yi-Jen Chang

News and Trends 20 Oct 2022

Sunshine Biopharma acquires Nora Pharma

Sunshine Biopharma Inc, a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, has completed the acquisition of all the outstanding shares of Nora Pharma Inc., effective immediately. Nora Pharma is now a wholly owned subsidiary of Sunshine Biopharma Inc. The addition of Nora Pharma allows Sunshine Biopharma to expand […]

October 20, 2022 - 3 minutesmins - By Jim Cornall

In Depth 20 Oct 2022

Opportunities and challenges for cell and gene therapy investments

Companies in the cell and gene therapy space are struggling to raise investments amid adverse market conditions. However, this could be an opportunity for the strongest companies and investors to shine. After several years of record-breaking investments, funding is hard to come by in the gene and cell therapy space. Part of this trend relates […]

October 20, 2022 - 9 minutesmins - By Jonathan Smith

News and Trends 20 Oct 2022

Tiziana Life Sciences looks to phase 1 trial for intranasal Alzheimer’s drug

Tiziana Life Sciences Ltd. says it plans to submit an investigational new drug (IND) application for a phase 1 trial of intranasal foralumab in Alzheimer’s disease patients. It comes after the company received an affirmative written response from the FDA on a pre-investigational new drug application (PIND). Tiziana plans on filing the IND for Alzheimer’s […]

October 20, 2022 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Beckley Psytech acquires Eleusis Therapeutics

Syncona to acquire Applied Genetic Technologies Corporation

New method of observing cell transport could inspire drug development

Sensorion gets go-ahead from France for trial of drug to prevent hearing loss

Mass production of lutetium for targeted cancer therapeutics following collaboration

Hiding in plain sight: how to solve bioscience’s software problem

Watch: NLS Days NLSInvest award winners – MyoPax

Beyond Biotech podcast 19: Bone Health Technologies, Immutep, TAU Systems

Meet Bárbara, our new sales representative

Sunshine Biopharma acquires Nora Pharma

Opportunities and challenges for cell and gene therapy investments

Tiziana Life Sciences looks to phase 1 trial for intranasal Alzheimer’s drug

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!